Illustration: Axios Visuals.
Fore Biotherapeutics plans to submit its cancer drug candidate to the FDA for approval in the second half of next year, CEO Bill Hinshaw tells Axios.
Why it matters: As the company hits milestones, it will likely need to fundraise again before 2027, Hinshaw says.
